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Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human
monoclonal antibody toproproteinconvertase subtilisin/kexin 9, comparedwithezetimibe, as add-on therapy tomaximally
tolerated statin therapy in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia.
Methods
and results
COMBO II is a double-blind, double-dummy, active-controlled, parallel-group, 104-week studyof alirocumab vs. ezetimibe.
Patients (n ¼ 720)with highcardiovascular risk and elevated LDL-Cdespitemaximaldoses of statins were enrolled (August
2012–May 2013). This pre-specified analysis was conducted after the last patient completed 52 weeks. Patients were ran-
domized to subcutaneous alirocumab 75 mg every 2 weeks (plus oral placebo) or oral ezetimibe 10 mg daily (plus subcuta-
neous placebo) on a background of statin therapy. At Week 24, mean+SE reductions in LDL-C from baseline were
50.6+1.4% for alirocumab vs. 20.7+1.9% for ezetimibe (difference 29.8+2.3%; P, 0.0001); 77.0% of alirocumab
and 45.6% of ezetimibe patients achieved LDL-C ,1.8 mmol/L (P, 0.0001). Mean achieved LDL-C at Week 24 was
1.3+0.04 mmol/L with alirocumab and 2.1+0.05 mmol/L with ezetimibe, and were maintained to Week 52. Alirocumab
was generally well tolerated, with no evidence of an excess of treatment-emergent adverse events.
Conclusion In patients at high cardiovascular risk with inadequately controlled LDL-C, alirocumab achieved significantly greater
reductions in LDL-C compared with ezetimibe, with a similar safety profile.
Trial registration clinicaltrials.gov Identifier: NCT01644188.
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Introduction
Hypercholesterolaemia is a major risk factor for the development
of atherosclerosis and coronary heart disease (CHD). Reducing
low-density lipoprotein cholesterol (LDL-C) with statins lowers the
risk of CHD events and all-cause mortality1 and there is a clear relation
between the degree of absolute LDL-C lowering and the degree of
cardiovascular event reduction.2 Consequently, LDL-C reduction is
the primary target to reduce cardiac events.3,4 Comparative data of in-
tensive vs. standard-dose statin treatment suggest that the lower the
LDL-C concentration, the greater the benefit in high cardiovascular
risk patients.2 The recommended treatment target for LDL-C is
,2.6 mmol/L (,100 mg/dL) in patients at high risk and ,1.8 mmol/
L (,70 mg/dL), or a ≤50% reduction from baseline, in those at very
high risk.4–6 Despite more widespread use of intensive statin therapy,
a substantial proportion of high-risk hypercholesterolaemic patients
donotachieveadequateLDL-Creduction.7,8 While the latestUSguide-
lines emphasize theuseof intensive statin therapy, they call forevidence
for new lipid-modifying agents to determine the incremental cardiovas-
cular disease event-reduction benefits on top of statin therapy.9 Such
therapies include fullyhumanmonoclonal antibodiesagainstproprotein
convertase subtilisin/kexin 9 (PCSK9), including alirocumab (formerly
SAR236553/REGN727) and evolocumab.10,11
Alirocumab reduces LDL-C concentrations by 40–70% in
combinationwithother lipid-loweringtherapies (LLT)orasmonother-
apy.12–14 Guided by these very large reductions, even in combination
with concomitant LLT, the COMBO II study (NCT01644188) was
designed to test the hypothesis of the superiorityof alirocumab vs. eze-
timibe in LDL-C reduction in patients at high risk for cardiovascular
events and who require additional pharmacological management
because theircurrent statin therapy failed toachieve their LDL-Ctreat-
ment goal. The selectionofdoses, dosing frequency, and dose-increase
approach was based on the LDL-C reduction needed to provide the
best achievement of the target LDL-C level at the lowest dose.
Methods
COMBO II is an ongoing double-blind, double-dummy, active-
controlled, parallel-group, 104-week study of alirocumab vs. ezetimibe
in high cardiovascular risk patients with inadequately controlled
hypercholesterolaemia on maximally tolerated doses of statins.15
The study was conducted at 126 sites (Europe, Israel, North America,
South Africa, South Korea) (Supplementary material online, Text S1),
with enrolment from August 2012 to May 2013. Results are
presented from a pre-specified analysis, including final efficacy results
up to Week 52 and safety data up to the date of the last patient
Week 52 visit.
The trial methods have been published.15 The principal study criteria
are shown in Supplementary material online, Table S1.15 Patients were
to have hypercholesterolaemia and established CHD or CHD risk-
equivalents (ischaemic stroke, peripheral artery disease, moderate
chronic kidney disease, or diabetes mellitus plus ≥2 additional risk
factors), and be treated with a maximally tolerated dose of statin
therapy [i.e. rosuvastatin 20/40 mg, atorvastatin 40/80 mg, or simvastatin
80 mg (if on this dose for .1 year)] or on a lower dose provided the
reason for doing so was documented. Statin dose had to be stable for
≥4 weeks before the screening visit and use of other LLT was not
permitted. At screening, patients with documented cardiovascular
disease (CVD) and LDL-C ≥1.8 mmol/L (≥70 mg/dL) or no
documented history of CVD but who were at high cardiovascular risk
and had LDL-C ≥2.6 mmol/L (≥100 mg/dL) were eligible to participate.
The study was performed in accordance with the principles of the
Declaration of Helsinki and all applicable amendments by the World
Medical Assemblies, and the InternationalConference on Harmonization
Guidelines for Good Clinical Practice. The protocol was approved by the
institutional review boards of participating centres. All participants gave
written informed consent.
Intervention
Eligible patients entered a screening period of up to 3 weeks before ran-
domization during which they were trained to self-inject using a prefilled
pen (autoinjector), vital signs were taken, a 12-lead electrocardiogram
was performed, and fasting blood and urine samples were obtained.
LDL-C was calculated using the Friedewald formula.16 For patients
whose triglycerides exceeded 4.5 mmol/L, the central laboratory automat-
ically measured LDL-C using the beta-quantification method (Medpace Ref-
erence Laboratories; Cincinnati, OH, USA; Leuven, Belgium; Singapore).
LDL-C was also measured at Weeks 0 and 24. Other lipid parameters
[total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycer-
ides, apolipoprotein B, and lipoprotein a] were measured directly by the
central laboratory (Medpace Reference Laboratories).
Eligible patients were randomized to alirocumab or ezetimibe
through an interactive voice response system (ALMAC company),
using a permuted-block design with a 2:1 allocation ratio. To attain
balance between arms for factors that may have influenced treatment re-
sponse, patients were stratified according to history of myocardial infarc-
tion or ischaemic stroke, intensity of statin treatment, and geographic
region. After randomization, patients entered a double-blind, double-
dummy treatment period lasting 104 weeks. Patients were randomized
to either subcutaneous (SC) alirocumab 75 mg (in 1 mL volume) every
2 weeks (Q2W) (plus oral placebo forezetimibe daily) or 10 mg oral eze-
timibe daily (plus placebo SC Q2W for alirocumab) and continued to
receive their background statin therapy. The dose in the alirocumab
arm (only) was automatically increased, per protocol, at Week 12 to
150 mg Q2W (1 mL volume) if the Week-8 LDL-C value was
≥1.8 mmol/L. Investigators and patients remained blinded to any dose
increase. The study is ongoing at the time of writing, and randomized
treatment will continue until Week 104, followed by an 8-week post-
treatment observational period.
Patients were instructed to remain on a stable diet [National Choles-
terol Education Program Adult Treatment Panel III (NCEP ATP III) thera-
peutic lifestyle changes diet17 or equivalent] and to maintain the same
daily statin dose throughout the study.
Outcomemeasures
The primary endpoint was percent change in calculated LDL-C from base-
line to Week 24, using all LDL-C values from Week 24 regardless of adher-
ence to treatment [intent-to-treat (ITT) approach]. Principal secondary
efficacy endpoints included: percent change in calculated LDL-C from
baseline to Week 24 (on-treatment analysis), and from baseline to
Weeks 12 (ITT/on-treatment analysis) or 52 (ITT analysis); percent
change in Apolipoprotein B, non-HDL-C, total cholesterol, lipoprotein a,
HDL-C, fasting triglycerides, and Apolipoprotein A-1 from baseline to
Week 24 (ITT analysis), and proportion of patients reaching calculated
LDL-C ,1.8 mmol/L at week 24 (ITT/on-treatment analysis).15
Safetywas assessedbyanalysing adverse-event reports (including adju-
dicated cardiovascular events and serious adverse events) and laboratory
analyses from the time of signed informed consent until the end of the
study. This process is described in detail elsewhere.15 Laboratory ana-
lyses for all safety parameters, except lipids, were performed by a
Efficacy and safety of alirocumab in high cardiovascular risk patients 1187
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central laboratory (COVANCE Laboratories; Indianapolis, IN, USA;
Geneva, Switzerland). In this analysis, all safety events were analysed
through the date of the database lock.
Statistical analyses
We estimated that a sample of 96 participants would have 95% power to
detect a difference in mean percent change in LDL-C of 20% at a signifi-
cance level of 0.05 for a 2-sided test, assuming a common standard devi-
ation of 25% and all 96 patients having an evaluable primary endpoint.
However, the sample size was set at 660 (2:1 randomization) to better
assess the safety of alirocumab in the context of this study and in the
overall integrated safety database of the ODYSSEY program.
The population for the primary efficacy analysis comprised randomized
patients with a calculated LDL-C value at baseline and at least one of
the planned time-points from Weeks 4 to 24, regardless of treatment
adherence (ITT population). The analysis was conducted after the last
patient completed the 52-week treatment period. The primary endpoint
was analysed using a mixed effect model with a repeated measures
(MMRM) approach to account for missing data. All available post-baseline
data at planned time-points from Week 4 to 52 regardless of status
on- or off-treatment were used in the MMRM for the ITT analysis, with
the model used to provide least-squares (LS) mean estimates and com-
parison between treatment arms of LDL-C reductions at week 24.
The models included fixed categorical effects of treatment group,
randomization strata, time-point, treatment-by-time-point interaction,
and strata-by-time-point interaction, as well as the continuous fixed
covariates of baseline LDL-C value and baseline value-by-time-point
interaction.
A hierarchical procedure was used to control type I error and to handle
multiple secondary endpoint analyses. Because the primary endpoint
analysis (ITT) was significant at the 5% alpha level, key secondary efficacy
endpoints were tested sequentially.15 LDL-C reduction at Week 24 was
analysed ‘on treatment’ in the pre-specified modified ITT (mITT) popula-
tion (i.e. all patients in the ITT population who had an evaluable primary
efficacy endpoint while on treatment, defined as the period between
first dose of study treatment up to 21 days after last injection, or 3 days
after taking the last capsule, whichever came first). For the on-treatment
analysis, all available on-treatment measurements (i.e. up to 21 days after
last injection or 3 days after the last capsule, whichever came first) at
planned time-points from Weeks 4 to 52 were used in the MMRM. A sen-
sitivity analysis, basedona patternmixturemodel,was conducted toevalu-
ate the impact of missing data on the primary endpoint; in this approach,
missing calculated LDL-C values during the ‘on-treatment’ period were
multiply imputed using a model assuming ‘missing at random’ and missing
calculated LDL-C values during the post-treatment period were multiply
imputed using random draws from a normal distribution where the
mean was equal to subject’s own baseline value.
Secondary endpoints comprising continuous variables with a normal
distribution were analysed using the MMRM model. Those secondary
endpoints with a non-normal distribution (lipoprotein a and triglycer-
ides) and the binary (non-continuous) variable secondary endpoints
were analysed using a multiple imputation approach for handling of
missing values followed by robust regression (for lipoprotein a and trigly-
cerides) or logistic regression (for the binary endpoints).
Safety analyses used a pre-specified cut-off corresponding to the last
patient visit at Week 52 and included all data collected between 52
and 104 weeks. Data are reported descriptively based on data from
randomized patients who received at least one dose or partial (in the
event that ,1 mL was injected) dose of study treatment.
The analysis was performed using SAS version 9.2 software (SAS Insti-
tute Inc., Cary, NC, USA).
Results
We screened 1112 high cardiovascular risk patients, 720 of whom
were eligible and consented to participate (Figure 1). Of these, 479
were randomly assigned to alirocumab and 241 to ezetimibe. The
mean+ standard deviation (SD) age was 61.6+9.3 years, 73.6%
of participants were men, 90.1% had CHD, and 30.7% had type 2 dia-
betes mellitus. Mean+SD body mass index (BMI) was 30.3+ 5.1 kg/
m2 and 113 (n ¼ 46.9%) had a BMI≥30 kg/m2. The mean+ SD base-
line calculated LDL-C concentration was 2.8+0.9 mmol/L; 66.7%
(n¼ 480) were taking atorvastatin 40/80 mg/day or rosuvastatin 20/
40 mg/day, and 2.1% (n ¼ 15) were on simvastatin 80 mg. The
reasons documented for taking a lower dose of statin are detailed
in Supplementary material online, Table S2. Baseline characteristics
were balanced between the two groups (Table 1).
The mean+ SD duration of injection exposure was 58.0+18.7
weeks (26.6+8.8 injections) in the alirocumab arm and 57.7+19.0
weeks (26.6+ 9.0 injections) in the ezetimibe arm. At the time of
this analysis, 84.8% of patients in the alirocumab arm and 85.5% in
the ezetimibe arm were receiving ongoing treatment (active or
placebo); 18.4% (82 patients) of patients in the alirocumab arm had
the dose increased at Week 12 to the 150 mg Q2W dosing
regimen because their LDL-C at Week 8 was ≥1.8 mmol/L.
Efficacy
For the primary endpoint, mean+ standard error (SE) reductions in
LDL-C from baseline to Week 24 were250.6+1.4% in the alirocu-
mab arm and 220.7+ 1.9% in the ezetimibe arm, both on a
background of maximally tolerated statin therapy, with a statistically
significant difference of the means+ SE between groups of 229.8
(95% CI 234.4 to 225.3, P, 0.0001) (Table 2). The results for
the on-treatment analysis (Table 2 and Supplementary material
online, Table S3) and the sensitivity analysis (Supplementary material
online,Table S4)wereconsistent with the primaryendpoint. The pro-
portion of patients who achieved the target LDL-C of ,1.8 mmol/L
atWeek 24 (ITT analysis) was 77.0% in the alirocumab arm and 45.6%
in the ezetimibe arm (P, 0.0001). The distribution of baseline and
achieved LDL-C values at 24 weeks is shown in Figure 2. The mean
achieved LDL-C at Week 24 was 1.3+ 0.04 mmol/L with alirocu-
mab and 2.1+ 0.05 mmol/L with ezetimibe.
The time-course of changes in LDL-C concentrations in the
alirocumab and ezetimibe arms from baseline to 52 weeks is shown
in Figure 3. Mean LDL-C concentrations dropped rapidly in the first
4 weeks, but to a greater degree in the alirocumab arm. The reduc-
tions achieved by 4 weeks remained largely constant up to 52 weeks.
The time-course of changes in LDL-C concentrations according to
dose-increase status in the alirocumab arm is shown in Supplemen-
tary material online, Figure S1.
Percent changes in other lipid measures are shown in Table 2
and Supplementary material online, Table S3. Statistically signifi-
cant mean+ SE reductions were observed for Apolipoprotein B
(22.4+ 1.8%), lipoprotein a (21.7+ 2.4%), and non-HDL-C
(22.9+2.0%) (all P, 0.0001), and there was an 8.1+ 1.3% increase
in HDL-C at Week 24 in the alirocumab arm compared with ezeti-
mibe (P, 0.0001). Triglycerides were reduced from baseline to
Week 24 by 13.0+1.5% in the alirocumab group and by 12.8+
2.0% in the ezetimibe group, but the difference between treatment
C.P. Cannon et al.1188
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arms was not statistically significant. Apolipoprotein A-1 concentra-
tions increased in the alirocumab group and decreased in the ezeti-
mibe group, but according to the hierarchical analysis rules, formal
analysis was stopped following the non-significant difference for
triglyceride reduction. C-reactive protein levels did not change
over time with alirocumab and were slightly lower with ezetimibe
(Supplementary material online, Table S5 and Figure S2).
Alirocumab efficacy vs. ezetimibe was consistent across several
subgroups in the ITT population.The results did not differ qualitative-
ly as a function of demographics, region, medical history, baseline
total/free PCSK9 concentration, diabetes (personal history), inten-
sity of statin treatment, or baseline lipid values (Supplementary
material online, Figure S3).
Safety
Rates of treatment-emergent adverse events (TEAEs) over a mean of
58+ 19 weeks’ follow-up are shown in Table 3. The overall percen-
tages of patients who experienced at least one TEAE were 71.2% in
the alirocumab arm and 67.2% in the ezetimibe arm. A TEAE leading
to death occurred in 0.4% (n ¼ 2) of patients in the alirocumab arm
(both of cardiac origin) and in 1.7% (n ¼ 4) of patients in the ezeti-
mibe arm (two of cardiac origin). Similar percentages of subjects in
both groups experienced a serious adverse event (18.8% alirocumab
vs. 17.8% ezetimibe). A higher proportion of patients in the alirocu-
mab group experienced TEAEs leading to treatment discontinuation
(7.5 vs. 5.4%), with no specific pattern in type of adverse event.
There was no imbalance in TEAEs at the system organ class level
(Supplementary material online, Table S6). The most common TEAEs
(occurring in ≥5% of patients from either treatment arm) were
upper respiratory tract infection, accidental overdose, dizziness, and
myalgia (Table 3). Adjudicated cardiovascular events were infrequent,
occurring in 4.8% (n ¼ 23) of the alirocumab group vs. 3.7% (n ¼ 9)
in the ezetimibe group. Treatment-emergent local injection site
reactions occurred in 2.5% of patients in the alirocumab arm vs. 0.8%
for ezetimibe/placebo injections (Table 3). Reactions were of mild
intensity, except for one of moderate intensity, and none were
serious; two events led to discontinuation in the alirocumab group.
Few neurocognitive events took place in either group (Table 3). Abnor-
malities in laboratory measurements were uncommon and occurred at
similar rates in both groups. Exceptions were the incidence of elevated
alanineaminotransaminase,whichwasmore frequent in thealirocumab
group, and impaired glucose control,which was less frequent in the alir-
ocumab group (Table 3 and Supplementary material online, Table S6).
One-hundred and five (22.8% of 460) patients in the alirocumab
arm and none in the ezetimibe arm had two consecutive LDL-C
values ,0.65 mmol/L during the treatment period. Rates of TEAEs
in this group were similar to those in the ezetimibe group, with
the exception of nasopharyngitis, which was more frequent in the
alirocumab group (Supplementary material online, Table S6).
Discussion
In this active-controlled, double-blind trial, alirocumabdemonstrated
superior efficacy in reducing LDL-C concentrations compared with
ezetimibe in high cardiovascular risk patients with inadequately
Figure 1 Patient flow chart.
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Table 1 Baseline characteristics (all randomized patients)a
Characteristic Alirocumabb (n 5 479) Ezetimibec (n5 241)
Age (years) 61.7+9.4 61.3+9.2
Men 360 (75.2) 170 (70.5)
Raced
White 404 (84.3) 206 (85.5)
Black or African American 21 (4.4) 7 (2.9)
Othere 54 (11.3) 28 (11.6)
Body mass index (kg/m2) 30.0+5.4 30.3+5.1
Cardiovascular history and risk factors
Any cardiovascular history/risk factor(s) 477 (99.6) 241 (100)
Coronary heart disease 437 (91.2) 212 (88.0)
Acute myocardial infarction 277 (57.8) 139 (57.7)
Silent myocardial infarction 11 (2.3) 4 (1.7)
Unstable angina 106 (22.1) 46 (19.1)
Coronary revascularization procedure 330 (68.9) 165 (68.5)
Other clinically significant CHD 184 (38.4) 82 (34.0)
CHD associated with ≥1 comorbidity (among hypertension, diabetes or moderate CKD)
and/or associated with other CVD (ischaemic stroke, peripheral artery disease)
366 (76.4) 178 (73.9)
Coronary heart disease risk-equivalent 151 (31.5) 72 (29.9)
Ischaemic stroke 40 (8.4) 20 (8.3)
Peripheral artery disease 24 (5.0) 11 (4.6)
Moderate CKD 61 (12.7) 23 (9.5)
Diabetes mellitus plus ≥2 additional risk factors 59 (12.3) 31 (12.9)
≥2 CHD risk-equivalents or 1 CHD risk-equivalent associated with
hypertension or diabetes
141 (29.4) 67 (27.8)
Diabetes mellitus type 1 2 (0.4) 0
Diabetes mellitus type 2 145 (30.3) 76 (31.5)
Laboratory values
HbA1c (%) 6.05+0.75 6.07+0.77
Lipid parameters
LDL-C (Friedewald formula) (mmol/L) 2.8+0.9 2.7+0.9
Range 0.6–7.9 1.0–6.3
Apolipoprotein B (g/L) 0.9+0.2 0.9+0.2
Total cholesterol (mmol/L) 4.8+1.1 4.8+1.1
Non-HDL-C (mmol/L) 3.6+1.0 3.5+1.0
Lipoprotein a (mmol/L) 1.0 (0.3, 2.5) 0.8 (0.3, 2.0)
Triglycerides (fasted) (mmol/L) 1.5 (1.1, 2.2) 1.6 (1.2, 2.3)
HDL-C (mmol/L) 1.2+0.3 1.2+0.4
C-reactive protein (nmol/L) 34.1+74.1 34.6+51.1
Statin therapy at randomization 478 (99.8) 241 (100)
Taking high-intensity statinf 320 (66.8) 160 (66.4)
Atorvastatin 237 (49.5) 118 (49.0)
Rosuvastatin 137 (28.6) 75 (31.1)
Simvastatin 105 (21.9) 49 (20.3)
Data are mean+ SD, n (%), or median (interquartile range) unless otherwise stated. To convert cholesterol measurements to mg/dL, divide by 0.02586; and to convert triglycerides
measurements to mg/dL, divide by 0.01129.
CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; HbA1c, glycated haemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; SC, subcutaneous; SD, standard deviation; Q2W, every 2 weeks.
aThere were no clinically or statistically significant between-group differences.
bAlirocumab 75 mg SC Q2W with a dose increase to 150 mg Q2W at Week 12 if Week 8 LDL-C was ≥1.8 mmol/L (≥70 mg/dL).
c10 mg/day oral ezetimibe.
dRace was self-reported.
eAsian, American Indian, Alaska Native, Other.
fHigh-intensity statin defined as 40–80 mg/day atorvastatin or 20–40 mg/day rosuvastatin.
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Table 2 Percent change from baseline to week 24 in LDL-C (ITT and on-treatment) and in secondary lipid parameters
(ITT)
All patients on maximally tolerated
statin therapya
Alirocumabb Ezetimibec Alirocumab vs. ezetimibe
LSmean
difference+ SE (%)
95% CI P-value
Primary endpoint: LDL-C
ITT n ¼ 467 n ¼ 240
LS mean+ SE change from baseline (%) –50.6+1.4 –20.7+1.9 –29.8+2.3 –34.4 to –25.3 ,0.0001
On-treatment n ¼ 464 n ¼ 235
Baseline LDL-C, mean+ SD (mmol/L) 2.8+0.9 2.7+0.9 – – –
Range 0.6–7.9 1.0–6.3
LS mean+ SE change from baseline (%) –52.4+1.3 –21.8+1.8 –30.6+2.2 –34.9 to –26.2 ,0.0001
Secondary lipid parameters (ITT),
LS mean+ SE change from baseline (%)
n ¼ 467 n ¼ 240
LDL-C (beta-quantification method)d –47.7+1.6 –18.0+2.2 –29.7+2.7 –35.0 to –24.4 ,0.0001
LDL-C (baseline to Week 12) –51.2+1.3 –21.8+1.8 –29.4+2.2 –33.7 to –25.1 ,0.0001
Apolipoprotein B –40.7+1.1 –18.3+1.5 –22.4+1.8 –26.0 to –18.8 ,0.0001
Non-HDL-C –42.1+1.2 –19.2+1.7 –22.9+2.0 –26.9 to –18.9 ,0.0001
Total cholesterol –29.3+0.9 –14.6+1.2 –14.7+1.5 –17.7 to –11.7 ,0.0001
Lipoprotein ae –27.8+1.4 –6.1+2.0 –21.7+2.4 –26.4 to –17.0 ,0.0001
HDL-C 8.6+0.8 0.5+1.1 8.1+1.3 5.4 to 10.7 ,0.0001
Triglycerides (fasted)e –13.0+1.5 –12.8+2.0 –0.3+2.5 –5.1 to 4.6 0.91
Apolipoprotein A-1 5.0+0.6 –1.3+0.8 6.3+1.0 4.3 to 8.3 ,0.0001f
CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; ITT, intention-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least squares; Q2W, every 2 weeks;
SC, subcutaneous; SE, standard error.
aOne patient was not on maximally tolerated statin therapy.
bAlirocumab 75 mg SC Q2W with a dose increase to 150 mg Q2W at Week 12 if Week 8 LDL-C was ≥1.8 mmol/L (≥70 mg/dL).
c10 mg/day oral ezetimibe.
dSensitivity analysis conducted in 180 patients in the ezetimibe group and 361 patients in the alirocumab group. P-value for descriptive purposes only.
eCombined estimate obtained by combining adjusted means+ SE from robust regression model analyses of the different imputed data sets (multiple imputation).
fP-value for descriptive purposes only (according to the hierarchical analysis, formal analysis was stopped after triglycerides, which were not statistically significant).
Figure2 Distribution by 10 mg/dL increments of LDL-C concentration at baseline and at Week 24 in patients on maximally tolerated statinsa and
alirocumab or ezetimibe. Comparison between Week 24 vs. baseline is descriptive and exploratory only, as data for all patients were not available at
Week 24. aOne patients was not on maximally tolerated statin therapy.
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controlled hypercholesterolaemia over and above that seen with
maximally tolerated doses of potent statins. A 50.6% reduction
in LDL-C was achieved with alirocumab, with a mean difference vs.
ezetimibe of 29.8%. This degree of efficacy translated to mean (SE)
on-treatment LDL-C values of 1.3+ 0.04 and 2.1+ 0.05 mmol/L
at Week 24, respectively, and a greater proportion of participants
reached the treatment target of ,1.8 mmol/L [or the even lower
potential target of ,1.3 mmol/L (,50 mg/dL)]. These results
were consistent across various patient subgroups. No safety con-
cerns were apparent in this ongoing study. The substantial difference
between arms in LDL-C lowering after 24 weeks was sustained
through follow-up to 52 weeks. With the recent preliminary data
from the IMPROVE IT trial just presented,18 the control arm of this
study could potentially now be considered the appropriate reference
for any new therapy.
In current practice, 45–60% of patients on LLT7,8,19 fail to achieve
the LDL-C goal (,1.8 mmol/L) per NCEP ATP III6 or European
guidelines.3,4 The proportion is even lower (18%) for those on
non-statin therapies.19 Even in randomized trials using high-dose
statins with high treatment adherence, .40% of patients fail to
achieve the target, leaving them at substantially increased risk of a
major cardiovascular event.20,21 Initial data from the IMPROVE IT
trial18 suggest that further lowering of LDL-C with the non-statin
agent ezetimibe reduces cardiovascular events, but this is being
studied in several large outcomes trials with other agents, including
with alirocumab.22,23 The data presented here suggest that addition
of alirocumab to a treatment regimen with maximally tolerated
statins will provide substantial lowering of LDL-C so that many
more patients can achieve LDL-C goals than by adding ezetimibe.
Furthermore, the maximum LDL-C response to a PCSK9 inhibitor
is greater with combination therapy, as in COMBO II, vs. monother-
apy (i.e. with no background lipid-lowering therapies),12 indicating a
possible additive effect, or synergy, with these two classes of drugs,
as also suggested in studies involving evolocumab.11
The COMBO II study included a strategy of individualized
goal attainment, with a pre-planned dose-increase in patients
who failed to reach the LDL-C target by Week 8. We hypothesized
that most patients would gain substantial lipid lowering (50%)
even with the starting dose, and this proved correct. Approxi-
mately 80% of patients treated with alirocumab did not require a
dose increase. Of note, the 18% alirocumab-treated patients
who required a dose increase had much higher mean baseline
LDL-C values vs. patients who did not require an increase. The
dose increase at 12 weeks led to an additional mean reduction of
10.5% in LDL-C. Furthermore, the absolute reduction in LDL-C
by Week 24 was slightly greater in the dose-increase group (1.6
vs. 1.5 mmol/L).
Alirocumab was generally well tolerated, with no evidence of an
excess of TEAEs, serious adverse events, or deaths in this ongoing
study. Injection site reactions occurred more frequently in the aliro-
cumab arm; these were mild in intensity in all but one case with mod-
erate intensity. The rate of adjudicated cardiovascular events was
slightly higher with alirocumab (4.8%) vs. ezetimibe (3.7%). Cardio-
vascular outcomes will be assessed in an ongoing study (http://
clinicaltrials.gov/show/NCT01663402)22 and in a pooled analysis
from overall ODYSSEY program. This study was limited to high car-
diovascular risk patients with inadequately controlled hypercholes-
terolaemia, but will complement the range of data emerging from
the ODYSSEY program. Further research is needed to evaluate the
efficacy of alirocumab in different racial groups. While the primary
endpoint in this study was LDL-C reduction at 24 weeks, the study
will continue up to 104 weeks to maximize available safety data and
generate information on the durability of alirocumab lipid-lowering
effects.15
Figure 3 LDL-C values achieved vs. study time-points (ITT analysis). Percentages above Weeks 12 and 24 data points indicate LS mean (SE)
percent change from baseline. Values above Weeks 24 and 52 indicate achieved LDL-C.
C.P. Cannon et al.1192
 by guest on M
ay 3, 2016
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
Conclusions
In this population of high cardiovascular risk patients with inadequately
controlled LDL-C on maximally tolerated doses of potent statins, alir-
ocumab produced significantly greater reductions in LDL-C vs. ezeti-
mibe using a dose-increase approach, with a comparable safety profile.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Table 3 TEAEsa and laboratory parameters (safety population) at 52 weeks
All patients on maximally tolerated statin therapyb Alirocumabc
(n 5 479)
Ezetimibed
(n 5 241)
Any TEAE 341 (71.2) 162 (67.2)
Treatment-emergent SAE 90 (18.8) 43 (17.8)
TEAE leading to deathe 2 (0.4) 4 (1.7)
TEAE leading to treatment discontinuation 36 (7.5) 13 (5.4)
TEAEs occurring in ≥5% of patients in either group or TEAEs of interest
Accidental overdosef 30 (6.3) 16 (6.6)
Upper respiratory tract infection 31 (6.5) 14 (5.8)
Dizziness 23 (4.8) 13 (5.4)
Myalgia 21 (4.4) 12 (5.0)
Injection-site reaction 12 (2.5) 2 (0.8)
Neurocognitive disorder 4 (0.8) 3 (1.2)
Adjudicated cardiovascular events 23 (4.8) 9 (3.7)
CHD death (including undetermined cause) 2 (0.4) 2 (0.8)
Non-fatal myocardial infarction 12 (2.5) 3 (1.2)
Fatal/non-fatal ischaemic stroke (including stroke not otherwise specified) 1 (0.2) 1 (0.4)
Unstable angina requiring hospitalization 1 (0.2) 0
Congestive heart failure requiring hospitalization 1 (0.2) 1 (0.4)
Ischaemia-driven coronary revascularization procedure 16 (3.3) 4 (1.7)
Laboratory parameters
Alanine aminotransferase .3 × ULN 8/470 (1.7) 1/240 (0.4)
Creatine kinase .3 × ULN 13/467 (2.8) 6/236 (2.5)
Data are n (%) or n/N (%). CHD, coronary heart disease; Q2W, every 2 weeks; SAE, serious adverse event; SC, subcutaneous; TEAE, treatment-emergent adverse event; ULN, upper
limit of normal.
aTEAEs are adverse events that developed or worsened or became serious during the TEAE period [defined as the time from the first dose of double-blind study treatment to the last
injection plus 70 days (10 weeks), as the residual effect of alirocumab was expected until 10 weeks after the last injection].
bOne patient was not on maximally tolerated statin therapy.
cAlirocumab 75 mg SC Q2W with a dose increase to 150 mg Q2W at week 12 if week 8 LDL-C was ≥1.8 mmol/L (≥70 mg/dL).
d10 mg/day oral ezetimibe.
eBoth deaths in the alirocumab arm were due to cardiovascular events (cardiac arrest and sudden cardiac death). Of the four deaths in the ezetimibe arm (malignant lung neoplasm,
suicide, defect conduction intraventricular plus sudden cardiac death, and sudden death—one patient was counted in two categories), two were due to cardiovascular events.
fAccidental overdose was an event suspected by the investigator or spontaneously notified by the patient (not based on systematic injection/capsule counts) and defined as at least
twice the intended dose within the intended therapeutic interval (i.e. ≥2 injections from the double-blind treatment kit administered in ,7 calendar days or ≥2 capsules from the
double-blind treatment kit were administered within 1 calendar day).
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